Regeneron Gains as Eye Drug Approved for Expanded Use

Regeneron Pharmaceuticals Inc. shares climbed to a four-month high after U.S. regulators approved its eye injection Eylea for use against diabetic macular edema, a disease in 1.5 million Americans that’s linked to vision loss.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.